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of non–ST-segment elevation acute coronary syndromes
(NSTE-ACS) that were published between June 2010 and
May 2011.
Background
Heidenreich et al. (1), in a document prepared for the
American Heart Association (AHA), forecasts that cardio-
vascular disease (CVD) prevalence and costs are projected to
continue to increase substantially, with more than 40% of
individuals having some form of CVD by 2030. Acute
coronary syndrome (ACS) represents the most common
initial presentation of CVD, and although rates of ST-
segment elevation myocardial infarction (STEMI) are fall-
ing, the proportion of all acute infarcts comprised by
non–ST-segment elevation myocardial infarction (NSTEMI)
increased from 53% to 77% in the past decade (Fig. 1) (2).
Treatment gaps persist despite publication of widely dis-
seminated practice guidelines, which are continually up-
dated (3,4).
2011 Guideline Focused Update
The American College of Cardiology Foundation and the
AHA released a focused update on the management of
patients with unstable angina and NSTEMI (3) in 2011
that incorporated new information since the previous ver-
sion in 2007. The key changes are summarized in Table 1.
The European Society of Cardiology updated its guideline
in 2011 as well (4).
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Considerable effort continues on understanding the natural
history of the progression of atherosclerosis, the relationship
between plaque morphology and type of ACS event, and the
prognosis in patients with coronary spasm. Characteristics of
coronary arterial plaques that favor development of an NSTE-
ACS (compared with STEMI) studied by using optimal
coherence tomography (OCT) include the absence of previous
plaque rupture (53% vs. 30%; p  0.033), absence of thin-cap
broatheromas (51% vs. 22%; p  0.008), and absence of red
hrombus (73% vs. 22%; p  0.001) (6). Furthermore, among
patients with unstable angina, the severity of symptoms varied
with plaque structure as identified by using OCT (7). Patients
with the most severe presentation (Braunwald class III [angina
at rest within 48 h]) were more likely to have thin-cap
fibroatheromas with spotty classifications (p 0.001 for both).
Patients with Braunwald class I symptoms had the highest
frequency of ulcers without fibrous cap disruption (p 0.003).
Table 2 provides a listing of the relevant study names and
acronyms discussed here. In the PROSPECT trial (8), 697
patients with ACS underwent coronary angiography and
intravascular ultrasound imaging after percutaneous coro-
nary intervention (PCI) to characterize culprit and noncul-
prit lesions throughout the coronary tree. Major cardiovas-
cular events over a median follow-up of 3.4 years occurred
equally at the site of lesions that had previously been
responsible for an ACS and those that had not (culprit vs.
nonculprit lesions). The nonculprit lesions were most fre-
quently nonobstructive (32  21% diameter stenosis by
angiography) and had a large plaque burden and/or luminal
area 4 mm2, characteristic of a high risk of future rupture
Fig. 2) (8). Therefore, to prevent future cardiovascular
vents, more intensive therapies directed at nonculprit
esions that are typically nonobstructive, yet vulnerable to
upture, are required.
However, the optimal imaging technique for identifying
ulnerable plaques remains to be identified. A comprehen-
ive review of the histological validation of a variety of
nvasive (e.g., intravascular ultrasound, palpography, OCT,
ear-infrared spectroscopy, intravascular magnetic reso-
ance imaging [MRI], angioscopy, thermoscopy, shear
tress imaging) and noninvasive (e.g., multidetector com-
2343JACC Vol. 58, No. 22, 2011 Giugliano and Braunwald
November 22, 2011:2342–54 Year in NSTE-ACSputed tomography, MRI, nuclear, ultrasound) imaging
techniques available to assess vulnerable plaques concluded
that the diagnostic and predictive accuracy of each of these
methods needs to be evaluated in large prospective studies
before they could be incorporated into clinical practice (9).
Inevitably, these techniques will have to be compared in
cost-effectiveness analyses.
Interestingly, the 3-year follow-up of the CASPAR
Study (10) of patients with coronary artery spasm as the
cause of ACS (more frequently associated with Braunwald
class II unstable angina, which had developed between 48
hours and 1 month earlier) demonstrated an excellent
prognosis, with no cardiac death or nonfatal myocardial
infarction (MI), compared with 11% in those with a
detectable culprit lesion. However, 50% of patients without
a culprit lesion continued to experience angina during the
3-year follow-up phase, which presents a challenge to the
quality of life in these patients with coronary spasm.
Risk Stratification
The 6 goals of cardiovascular risk assessment are to:
1) achieve effective triage; 2) direct the need for additional
testing; 3) identify patients who need referral to a subspe-
Figure 1 Age- and Sex-Adjusted Incidence Rates of
Acute Myocardial Infarction, 1999 to 2008
MI  myocardial infarction; NSTEMI  non–ST-segment elevation myocardial
infarction; STEMI  ST-segment elevation myocardial infarction. Reprinted, with
permission, from Yeh et al. (2).
Major Modifications to the 2011 NSTE-ACS Practice GuidelineTable 1 Major Modifications to the 2011 NSTE-ACS Practice G
1. Recommends selective use of drugs to minimize the risk of recurrent gastrointes
gastrointestinal bleeding who are being treated with aspirin and clopidogrel (5)
2. Recommends the administration of a loading dose of clopidogrel (300–600 mg)
3. Extended the recommended duration of thienopyridine therapy to at least 12 mo
bleeding outweighs the anticipated benefits
4. Deleted the recommendation of aggressive glycemic management in patients wi
5. Deleted the recommendation to preferentially use isomolar contrast agents in pa
6. Added recommendations in patients undergoing angiography with chronic kidney
a. Receive adequate preparatory hydration before angiography
b. Calculate a contrast volume to CrCl ratio to predict the maximum volume of c
associated nephropathySee Wright et al. (3) for a detailed comparison of the new versus old guidelines.
CrCl  creatinine clearance; NSTE-ACS  non–ST-segment elevation acute coronary syndromes; PCI cialist; 4) guide therapeutic decision making; 5) optimize
allocation of clinical resources; and 6) inform patients and
families of the prognosis (11). Research reported during the
past year added new information that helps clinicians attain
these goals.
Numerous triggers of plaque rupture and MI have been
identified, but new data incorporating both the strength of
the relationship and the prevalence of exposure to calculate
a population-attributable risk fraction have become available
(12). Factors with the greatest population-attributable risk
for triggering an MI were traffic exposure, physical exertion,
alcohol, coffee, and air pollution. Among these triggers, a
large body of new information on particulate matter (PM)
air pollution led to a recent update to the AHA 2004
Scientific Statement on this subject (13). The key findings
were that exposure to fine PM (i.e., 2.5 M in diameter)
in the short-term (few hours to weeks) increases the risk for
CVD-related mortality, hospitalizations, and ischemic heart
disease, whereas longer-term exposure reduces life expec-
tancy. Thus, the AHA deemed PM 2.5 M to be a
modifiable factor that contributes to cardiovascular morbid-
ity and mortality, including both fatal and nonfatal ischemic
heart disease. Gersh et al. (14) reviewed how hostile factors
in the environment (e.g., air pollutants) interact with
predisposing factors of cardiovascular events and genetic/
phenotypic vulnerability, thus leading to the current epi-
demic of cardiovascular disease in low- and middle-income
countries (Fig. 3).
New data on risk stratification from a multinational
observational study in the Asia-Pacific region identified a
very-low-risk profile of patients who present to the emer-
gency department with chest pain. All patients had chest
discomfort lasting at least 5 min consistent with NSTE-
ACS and plans for serial biomarker assessment. Use of the
Thrombolysis In Myocardial Infarction (TIMI) risk score
for unstable angina (15) and a point-of-care biomarker
panel of troponin, creatine kinase-myocardial band, and
myoglobin, in addition to a standard 12-lead electrocardio-
gram as part of a 2-h accelerated diagnostic protocol,
classified 9.8% of patients as low risk (0.9% rate of major
adverse cardiac events through 30 days) with a sensitivity of
ine
leeding (e.g., proton pump inhibitors) in patients with a history of
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Year in NSTE-ACS November 22, 2011:2342–5499.3% and a negative predictive value of 99.1% (16). Thus,
by combining multiple modalities of risk assessment in a
2-h evaluation, 1 in 10 patients who present with clinical
symptoms of NSTE-ACS can be safely discharged home.
Figure 2 Event Rates in the PROSPECT Study Stratified Accord
The rates of cardiac death, cardiac arrest, myocardial infarction, or hospitalization
neous coronary intervention are shown for nonculprit lesions characterized using i
2,114), with or without a minimal luminal area (MLA) 4 mm2 and/or plaque burd
phy. CI  confidence interval; PROSPECT  Providing Regional Observations to St
et al. (8).
Trial AcronymsTable 2 Trial Acronyms
Acronym
ACCOAST A Comparison of Prasugrel at the Time of Percutaneou
Non-ST Elevation Myocardial Infarction
ACTION Acute Coronary Treatment and Intervention Outcomes
APPRAISE 2 Apixaban for Prevention of Acute Ischemic Events 2
ARCHIPELAGO Irbesartan in Patients With Acute Coronary Syndromes
ATLAS-ACS 2 The Second Trial of Anti-Xa Therapy to Lower Cardiova
AVANT GARDE Aliskiren and Valsartan to Reduce NT-pro–B-type Natri
CASPAR Coronary Artery Spasm in Patients with acute Coronar
COGENT Clopidogrel and the Optimization of Gastrointestinal E
CURE Clopidogrel in Unstable Angina to Prevent Recurrent E
CURRENT Clopidogrel Optimal Loading Dose Usage to Reduce R
ExTRACT Enoxaparin and Thrombolysis Reperfusion for Acute M
FUTURA Fondaparinux Trial With Unfractionated Heparin During
GRACE Global Registry of Acute Coronary Events
GRAVITAS Gauging Responsiveness With a VerifyNow Assay—Im
GWTG Get With The Guidelines
ISAR-REACT Intracoronary Stenting and Antithrombotic Regimen: R
LANCELOT Lessons From Antagonizing the Cellular Effect of Throm
MERLIN Metabolic Efficiency With Ranolazine for Less Ischemi
OASIS Optimal Antiplatelet Strategy for Interventions
PLATO Platelet Inhibition and Patient Outcomes
PROSPECT Providing Regional Observations to Study Predictors o
PROVE-IT Pravastatin or Atorvastatin Evaluation and Infection Th
SYNTAX Synergy Between Percutaneous Coronary Intervention
TIMI Thrombolysis In Myocardial Infarction
TRILOGY ACS Targeted Platelet Inhibition to Clarify the Optimal Stra
TRITON Trial to Assess Improvement in Therapeutic OutcomesFollow-up beyond 30 days would be of interest to establish
the long-term safety of this approach.
At the other end of the risk spectrum, patients in the
MERLIN-TIMI 36 trial, who experienced nonsustained
o Lesion Type
stable angina or progressive angina through a median of 3.4 years after percuta-
cular ultrasound as thin-cap fibroatheromas (TCFA) (n  595) or not TCFA (n 
) 70%. The inset shows a TCFA imaged by using radiofrequency ultrasonogra-
edictors of Events in the Coronary Tree. Reprinted, with permission, from Stone
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November 22, 2011:2342–54 Year in NSTE-ACSventricular tachycardia as short as 4 to 7 beats on continuous
electrocardiographic recording during the first 7 days after
an NSTE-ACS, had an adjusted hazard ratio (HR) for
sudden cardiac death of 2.3 (p 0.001) (17). Whether such
patients may benefit from electrophysiological evaluation
requires further prospective assessment. Other specific sub-
groups of patients with ACS at particularly high risk and
who may require referral to a subspecialist include patients
with depressive symptoms (18) and those infected with
human immunodeficiency virus (19).
Biomarkers
Pletcher and Pignone (20) published a comprehensive
review of the clinical utility of biomarkers, focusing on
methods to estimate their clinical impact on the patient and
clinical decision making. Judged in this context, the most
important development in the past year for ACS was the
further implementation of sensitive troponin assays, which
increased the frequency of diagnosis of MI (21) and iden-
tified additional patients at high risk of reinfarction and
death (21,22). In a single-center, prospective evaluation,
lowering the diagnostic threshold of a sensitive troponin I
assay from 0.20 to 0.05 ng/ml reclassified patients with
troponin values of 0.05 to 0.19 ng/ml as NSTEMI instead
of unstable angina (21). This reclassification resulted in
more aggressive treatment of patients with this lower-level
“positive” troponin, a reduction in morbidity and mortality
(21), and explains in part the increasing incidence of
NSTEMI over the past decade (Fig. 1).
Despite the wider adoption of more sensitive troponin
assays, 2 large multicenter registries identified 2 groups of
patients with NSTEMI who are still less likely to receive
guideline-recommended therapy although their biomarker
pattern satisfied current criteria for MI. Use of initial
antiplatelet and anti-ischemic therapy, statins, and long-
Figure 3 Factors Contributing to the Epidemic of Cardiovascular
Disease in Low- and Middle-Income Countries
CV  cardiovascular; HIV  human immunodeficiency virus.
Reprinted, with permission, from Gersh et al. (14).term clopidogrel were underused in patients with an ele- pvated troponin but normal creatine kinase-myocardial band
(i.e., troponin , myocardial band ) (23) as well as
patients in whom the first troponin values were negative but
who were subsequently ruled-in for NSTEMI (24). These
findings identify opportunities to improve clinical decision
making with serial measurement and proper interpretation
of more sensitive troponin assays.
One disadvantage of the use of more sensitive troponin
assays is the higher rate of false positives, which can lead to
the use of acute pharmacological therapies and coronary
angiography in patients who do not have NSTE-ACS (25).
Indeed, they may not even have ischemic heart disease (26).
areful consideration of the clinical context of the elevated
roponin and use of serial and/or multimarker strategies (as
iscussed in the following text) are methods that can reduce
he misinterpretation of such findings.
Elevated levels of midregional pro-adrenomedullin
sAM), a peptide fragment of the vasodilatory peptide
drenomedullin known to be elevated in heart failure and
ost-ACS, was prognostic for death or heart failure in
atients with NSTEMI (27). Admission levels of sAM were
ndependently associated with mortality at 30 days, even
fter adjustment for the GRACE score and N-terminal
ro–B-type natriuretic peptide (NT-proBNP). However,
hether heart failure biomarkers are useful for guiding
reatment decisions and improving outcomes—the most
mportant test of a biomarker (28)—remain a challenge.
hen such a strategy was tested in the AVANT GARDE–
IMI 43 trial of patients post-ACS with left ventricular
jection fraction (LVEF) 0.40, no overt heart failure, and
levated B-type natriuretic peptide (BNP), the addition of
liskiren, valsartan, or their combination did not reduce
evels of natriuretic peptides over an 8-week period com-
ared with placebo (29).
Newer research on neopterin and heart-type fatty acid–
inding protein have built on previous results described in
ur 2009 publication (30). In the PROVE IT–TIMI 22
rial in post-ACS patients, neopterin, a marker of monocyte
ctivation, was found to be an independent predictor of
ubsequent hospitalization for heart failure, and it improved
isk prediction when it was added to models including
raditional risk factors, high-sensitivity C-reactive protein
hsCRP), and BNP in patients post-ACS enrolled in the
ROVE IT–TIMI 22 trial (31). Heart-type fatty acid–
inding protein was shown to be an independent predictor
f death or MI. Among patients with suspected ACS and
ormal troponin, it was used to identify patients at high risk
or adverse events (32).
Progress has also been made in the use of multimarker
trategies in the assessment of risk in patients with NSTE-
CS. In an analysis of 4,352 patients with NSTE-ACS
nrolled in the MERLIN–TIMI 36 trial, both troponin I
nd NT-proBNP substantially improved risk prediction
hen added to clinical risk variables, whereas the inflam-
atory biomarkers myeloperoxidase and hsCRP did not
rovide additional prognostic information (33). Of 9 in-
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sured within 48 hours after symptom onset in 440 patients
with NSTE-ACS enrolled in the ARCHIPELAGO trial,
levels of interleukin-6 (which stimulates the hepatic synthe-
sis of C-reactive protein) was independently correlated with
subsequent ischemic endpoints (34). Meanwhile, the com-
bination of BNP, aldosterone, and matrix metalloproteinase-9,
when added to the GRACE clinical risk score, predicted
heart failure. In another study of 10 biomarkers measured in
448 subjects with suspected NSTE-ACS presenting to 5
US emergency departments, those with a trio of markers
(troponin I, BNP, and placental growth factor) with normal
values identified a very-low-risk cohort with event-free rates
at 30 and 365 days of 97% and 96%, respectively (35).
In summary, we believe that the most likely advances in
the past year from the biomarker field which will have a
lasting impact on the clinical practice of patients with
NSTE-ACS are the introduction of ultrasensitive troponin
assays and the concept of multimarker strategies to identify
very-low-risk cohorts.
Imaging
Cardiac MRI using a rapid-scan protocol can evaluate
ventricular wall edema, perfusion, wall motion, and identify
myocardium at risk in patients with NSTE-ACS (36). Such
findings could then be helpful in guiding PCI in patients
Figure 4 Myocardial Edema at Initial Presentation With NSTE-A
Magnetic resonance images in a patient with non–ST-segment elevation acute cor
post-gadolinium enhancement (B) consistent with irreversible injury. There is corre
systole (C) compared with end-diastole (D) of a vertical long-axis cine. LA  left awith multiple lesions or those with equivocal findings at
coronary arteriography (Fig. 4).
Several studies published in the past year have demon-
strated the prognostic utility of echocardiography in the
evaluation of patients with NSTE-ACS. In such patients
with preserved LVEF, echocardiographic findings of me-
chanical dyssynchrony were associated with an increased
risk of heart failure (37). Another study from the GRACE
registry reported that women with a supernormal LVEF
(65%) had a 2.5-fold increase in the odds of both
in-hospital death and cardiac arrest/ventricular fibrillation
(38), possibly related to diastolic dysfunction and/or the
presence of hypertrophic heart disease. Several echocardio-
graphic parameters, including abnormal segmental myocar-
dial perfusion using contrast echocardiography (39), abnor-
mal wall motion (39,40), tricuspid annular plane systolic
excursion (40), and ultrasound lung comets (extravascular
lung fluid observed on ultrasound thoracic scanning) (40),
added prognostic information to standard risk scores such as
the TIMI unstable angina risk score (15) and the GRACE
risk score in ACS (41).
Treatment
Antiplatelet agents. Platelets play a central role in the
pathogenesis of NSTE-ACS and hence antiplatelet agents
play an equally important role in its management. Clopi-
syndromes (NSTE-ACS) demonstrating infero-apical edema (A, arrow) and late
ing wall motion abnormality indicated by abnormal myocardial thickening at end-
V  left ventricular. Reprinted, with permission, from Raman et al. (36).CS
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November 22, 2011:2342–54 Year in NSTE-ACSdogrel, the most widely used P2Y12 platelet receptor–
locking agent, exhibits substantial interpatient variability
n its antiplatelet effect. Studies of various strategies to
nsure a more uniform higher antiplatelet effect—namely,
he use of higher-dose regimens, dose modification in
atients with a measured or predicted low antiplatelet effect,
nd use of more potent antiplatelet agents—dominated the
ast year in antiplatelet research in NSTE-ACS. In the
URRENT–OASIS 7 trial (42), a loading dose of 600 mg
f clopidogrel followed by 150 mg daily for 6 days and 75
g daily thereafter did not reduce the primary composite
ndpoint (cardiovascular death, MI, and stroke through 30
ays) compared with standard-dose clopidogrel (300-mg
oading dose, 75-mg daily maintenance dose) in the entire
tudy population of 25,086 with ACS or among the 17,759
ith NSTE-ACS (double-dose 4.2%; standard dose clopi-
ogrel 4.4% [p  0.30]). Meanwhile, double-dose clopi-
dogrel, but not higher-dose aspirin, was associated with
more major bleeding and red blood cell transfusions
(double-dose vs. standard-dose clopidogrel HR: 1.24 [95%
CI: 1.05 to 1.46]; higher-dose vs. lower-dose aspirin HR:
0.99 [95% CI: 0.84 to 1.17]). Although double-dose clopi-
dogrel was associated with a 14% relative reduction (p 
0.039) in the primary cardiovascular composite in a post-
randomization subgroup analysis of patients who underwent
PCI (43), the ability to predict who will need PCI is difficult
in patients with NSTE-ACS, and this benefit should be
weighed against the statistically significant 41% relative
increase in major bleeding (43). Even when tested among
patients with high platelet reactivity after drug-eluting
coronary stenting, double-dose clopidogrel (compared with
the standard dose) did not reduce the primary composite of
cardiovascular death, MI, or stent thrombosis among 2,214
patients enrolled in the GRAVITAS trial (44). Similarly,
there were no differences in cardiovascular ischemic events
between higher-dose (300 to 325 mg daily) or lower-dose
Figure 5 Cardiovascular Death, Myocardial Infarction, or Ische
Among patients treated with clopidogrel, hazard ratios are reported for cardiovascu
function CYP2C19 alleles versus noncarriers. Size of data markers reflects the sta
indicates the 95% confidence interval (CI) for the overall hazard ratio. The number
from Mega et al. (45) and reproduced with permission.(75 to 100 mg daily) aspirin in the overall cohort or among
those with NSTE-ACS in the CURRENT-OASIS 7 trial.
Two large meta-analyses, one involving 9 studies in 9,685
patients undergoing PCI (55% of whom had ACS [Fig. 5])
(45) and the second involving 10 studies in 11,959 patients
with an indication for clopidogrel (46), were reported. Both
concluded that reduced-function CYP2C19 alleles expose
patients treated with clopidogrel to an increased risk of
cardiovascular events, stent thrombosis, and cardiovascular
death. A pharmacodynamic hyporesponse to clopidogrel can
be overcome in 88% of patients with the 2C19*2 loss of
function polymorphism by using repeated loading doses of
clopidogrel 600 mg. However, as many as 3 additional doses
of 600 mg over 24 h may be needed (hence limiting the
practical application), and the clinical benefit of such large
doses has not been evaluated (47). An analysis of patients
with NSTE-ACS from the CURE trial did not show an
interaction between CYP2C19 genotype and either efficacy
or bleeding with clopidogrel (compared with placebo) (48).
However, the infrequent use (21%) of PCI in CURE may
explain, in part, the lack of an effect of the CYP450
genotype in these studies.
Two studies reported conflicting results regarding the
impact of paraoxonase-1 (PON1), an enzyme involved in
clopidogrel bioactivation, on platelet aggregation and stent
thrombosis in patients receiving clopidogrel after intracoro-
nary stenting (49,50). Bouman et al. (49) found, using in
vitro testing, that conversion of 2-oxo-clopidogrel to the
thiol compound was the rate-limiting step of clopidogrel
bioactivation, with PON1 representing the key enzyme. In
a case-control analysis of 41 patients with nonfatal stent
thrombosis compared with 71 randomly selected subjects
without stent thrombosis, individuals with the PON1
QQ192 genotype were more frequently represented in the
stent thrombosis group than in the control group (odds ratio
[OR]: 3.6 [95% CI: 1.6 to 7.9]; p  0.003) . However, in
troke by CYP2C19 Genotype
ath, myocardial infarction, or ischemic stroke among carriers of 1 or 2 reduced-
l weight of the study in the meta-analysis. Data marker for the overall category
nts and of individuals at risk for events is presented for each study. Modifiedmic S
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and 1,439 patients without early stent thrombosis, platelet
aggregation values were similar across all PON1 genotype
groups (p  0.65) and no differences were observed for
PON1 genotype distributions (p  0.23) (50). Additional
arger and preferably prospective studies are needed to
stablish whether PON1 genotype is an important risk
actor for stent thrombosis.
Use of one of the more potent antiplatelet agents,
rasugrel (51) or ticagrelor (52), not only achieves a higher
egree of platelet inhibition than clopidogrel but also
aintains superior efficacy, regardless of CYP2C19 or
BCB1 genotype (53). Furthermore, in a meta-analysis of 8
tudies of 48,599 patients undergoing PCI (regardless of
enotype) comparing one of the newer more potent PGY12
inhibitors with clopidogrel, the newer agents reduced mor-
tality (OR: 0.85 [95% CI: 0.75 to 0.96]) (54). The mortality
benefit of a more potent PGY12 inhibitor tended to be
reater among patients undergoing primary PCI for
TEMI (OR: 0.78 [95% CI: 0.66 to 0.92]).
Among 1,261 patients who underwent coronary artery
ypass graft (CABG) surgery enrolled in the PLATO
rial (reviewed in 2010 [55]), ticagrelor was as effective at
educing the primary composite of cardiovascular death,
I, and stroke as it was in the trial overall (HR: 0.84).
hus, there seems to be a benefit that exists outside of the
eri-PCI period as well. Ongoing studies are evaluating
he potential benefit of prasugrel in NSTE-ACS outside
f the peri-PCI window, including before PCI, in the
CCOAST trial (56), and in patients who are medically
anaged without planned PCI, in the TRILOGY ACS
rial (57).
Blockade of the protease-activated receptor 1 on platelets
site of thrombin binding) represents another promising
arget to inhibit platelet function (also reviewed in 2010
55]). Two Phase II trials (LANCELOT-ACS [58] and a
ister study conducted in Japan [59]) demonstrated the
afety and feasibility of blocking this receptor with atopaxar,
ith a reduction in ischemia observed on Holter monitoring
58). However, significant dose-dependent increases in liver
unction abnormalities and prolongation of the QT intervals
ere observed in the Japanese trial (59). A large phase III
rial with vorapaxar in patients with ACS was stopped early
ue to an increased risk of bleeding in patients with prior
troke at the request of the Data Safety Monitoring Board
60), and results are expected in late 2011.
Although it has been established that proton pump
nhibitors (PPIs) reduce the measurable antiplatelet effect of
lopidogrel in the laboratory (61), the clinical relevance of
his interaction remains controversial (5). A meta-analysis of
3 trials involving 48,674 subjects treated with clopidogrel for
variety of indications concluded that PPIs increased the
dds of major cardiovascular events and mortality by 41%
nd 18%, respectively (both p  0.001) (46). However, a
rench registry of 3,670 patients with acute MI did not find
ny differences in cardiovascular events or mortality for matients administered clopidogrel with a PPI versus without
PPI within 48 h after admission (62). In the COGENT trial
63), the only large placebo-controlled randomized trial
valuating the clinical risks and benefits of PPI when added
o clopidogrel and aspirin in patients with ACS or PCI,
here was no increase in cardiovascular events with omepra-
ole (HR: 0.99 [95% CI: 0.68 to 1.44]), whereas gastroin-
estinal events were substantially reduced (HR: 0.34 [95%
I: 0.18 to 0.63]).
leeding
emorrhagic complications in patients with NSTE-ACS
ot only add to the discomfort and morbidity experienced
y patients but are fatal in rare instances and also lower the
ikelihood of oral antiplatelet therapy prescription at dis-
harge (64); the latter increases the risk of subsequent
schemic events. In an analysis of Canadian patients with
STE-ACS enrolled in 4 registries, rates of major bleeding
emain relatively low (1.7%) and do not seem to have
ncreased over the past decade despite the increased use of
ual antiplatelet therapy and invasive procedures (65).
eanwhile, a large U.S. MI registry of patients more
requently managed with an invasive approach reported
ates of major bleeding that were 5-fold higher (66).
Although bleeding clearly adds to patient morbidity,
nalyses of patients with STEMI in the EXTRACT–TIMI
5 trial (67) and, more recently, in patients with ACS
ndergoing PCI in the TRITON–TIMI 38 trial (68) have
rawn attention to the complexities inherent in analyses that
valuate impact of bleeding on subsequent clinical outcomes
uch as mortality. Two important challenges identified in
hese analyses are the presence of a large amount of
onfounding due to differences in baseline characteristics
hen comparing outcomes in patients who bleed versus
hose who do not. Serious bleeding has been found to be
ssociated with an increase in subsequent adverse events, but
t is the patients at high risk of clinical events who have a
reater likelihood of bleeding (Fig. 6).
Approaches to reduce bleeding (and hence improve
hort- and long-term outcomes) have included risk assess-
ent with subsequent adjustment in the medical and/or
nvasive strategy, use of new potentially safer agents, reduc-
ion in the intensity of the antithrombotic regimen, and
mplementation of strategies to mitigate bleeding. Several
tudies explored new or modified bleeding scores in an
ttempt to better estimate the risk of bleeding in patients
ith NSTE-ACS and help guide therapy. An integer risk
core based on 6 baseline measures plus anticoagulation
egimen performed well in the identification of patients at
ncreased risk for non–CABG-related bleeding and mortal-
ty at 1 year in 2 trials with bivalirudin in patients with ACS
Table 3) (69). A model using 12 factors to predict in-
ospital major bleeding from the ACTION Registry-
WTG database was derived and validated in a total of
ore than 80,000 patients with MI, demonstrating good
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and validation cohorts, respectively) (70). How these newer
models compare with the more established CRUSADE
bleeding risk score (71) remains to be seen.
Another strategy to reduce bleeding is to tailor the
antithrombotic regimen for patients based on their pre-
dicted risk of bleeding. An analysis from the ACTION
registry (72) showed that lower rates of bleeding could be
achieved in patients with ACS undergoing PCI with a less
intensive antithrombotic regimen (either unfractionated
heparin [UFH] or bivalirudin monotherapy). A reduction in
Figure 6 Death After Different Types
of Bleeding in the TRITON–TIMI 38 Study
Hazard ratios (red) and 95% confidence intervals (blue) for death according to
time after different types of bleeding. Each red dot represents the hazard ratio
for death at the corresponding day after bleeding event compared with patients
at the same time in the trial without a bleeding event. Spontaneous bleeding
events were associated with a greater risk of death, although the hazard ratios
for both spontaneous and instrumented/traumatic bleeding events declined
rapidly in the first few days, and spontaneous bleeding did not differ statisti-
cally from 1.0 after 5 and 32 days, respectively. TRITON-TIMI 38  Trial to
Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition
With Prasugrel—Thrombolysis In Myocardial Infarction 38. Reprinted, with per-
mission, from Hochholzer et al. (68).bleeding was observed even though the patients who re-
s
Wceived the less intensive antithrombotic regimen were pre-
dicted to be at high risk of bleeding compared with those
who received a more intensive antithrombotic regimen
(combining an anticoagulant with a glycoprotein IIb/IIIa
inhibitor). Whether the reduction in bleeding that can be
achieved with a less intensive antithrombotic regimen would
be offset by an increase in ischemic complications in these
patients will require further prospective evaluation.
One important study that investigated a novel anticoag-
ulant regimen was the FUTURA/OASIS 8 trial in which a
strategy of fondaparinux 2.5 mg subcutaneously before PCI
followed by a standard UFH regimen of 85 U/kg bolus
(reduced to 60 U/kg if a glycoprotein IIb/IIIa antagonist
was used), with additional boluses guided by activated
coagulation time measurements, was as safe as a low-dose
UFH regimen of 50 U/kg (73). Thus, for patients with
Mehran Integer Bleeding Risk ScoreTable 3 Mehran Integer Bleeding Risk Score
Risk Factor Score
Female 8
Age (yrs)
50–59 3
60–69 6
70–79 9
80 12
Creatinine (mg/dl)
1.00–1.19 2
1.20–1.39 3
1.40–1.59 5
1.60–1.79 6
1.80–1.99 8
2.00 10
WBC (106/l)
10.0–11.9 2
12.0–13.9 3
14.0–15.9 5
16.0–17.9 6
18.0–19.9 8
20.0 10
Anemia present 6
Type of ACS
STEMI 6
NSTEMI 2
Antithrombotics regimen
Bivalirudin, no GPI 5
Risk Category (Sum Score) Example Predicted Bleed Rate*
Low (10) 0 0.9%
5 1.6%
Moderate (10–14) 10 2.8%
High (15–19) 15 4.7%
Very high (20) 20 7.9%
25 12.9%
30 20.4%
*Predicted rate of non–coronary artery bypass graft major bleeding within 30 days of ACS. Adapted
from Mehran et al (69).
ACS  acute coronary syndrome; GPI  glycoprotein IIb/IIIa inhibitor; NSTEMI  non–ST-
egment elevation myocardial infarction; STEMI  ST-segment elevation myocardial infarction;
BC  white blood cell count.
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UFH in the catheterization laboratory guided by activated
coagulation time is a reasonable antithrombotic strategy to
support PCI.
Factor IXa represents a new and interesting target for
inhibition in patients with PCI and ACS. Phase II data
with a reversible parenteral direct factor IXa inhibitor in
patients undergoing PCI were shown to be simple, safe, and
effective during PCI (74). We look forward to future studies
comparing the clinical outcomes of this approach with
current standard anticoagulant agents.
Reducing the dose of current standard antithrombotic
agents represents an alternate approach to minimizing
bleeding. In the ISAR-REACT 3A study (75), patients
with negative biomarkers treated with UFH and clopidogrel
before PCI had less bleeding without compromising isch-
emic protection when a lower single-bolus dose of heparin
(100 U/kg) compared with the standard UFH regimen in
Germany of 140 U/kg was used. In these low-risk patients,
there seems to be little evidence to support the use of
intensive antithrombotic regimens, and lower doses seem to
be safer.
Among patients undergoing PCI, other options to reduce
bleeding include the use of femoral arterial closure devices,
bivalirudin monotherapy (in place of UFH or low
molecular-weight-heparin) and use of radial (instead of
femoral) arterial access. The use of femoral closure
devices in patients treated with bivalirudin without a
glycoprotein IIb/IIIa inhibitor was associated with a low
rate of bleeding complications (76). However, an analysis
from the ACTION registry showed that this approach
paradoxically tended to be used least frequently in pa-
tients at highest risk for bleeding (69). An alternative
strategy is to use radial arterial access. In a randomized trial
comparing radial and femoral arterial access (77), radial
access was associated with fewer vascular complications and
a 60% reduction in the odds of a large hematoma; there was
no difference in the primary composite of death, MI, stroke,
or non–CABG-related bleeding. Thus, interventional car-
diologists have options to reduce bleeding, whether they
have been trained in radial arterial access or the more
traditional femoral arterial access.
Lastly, because patients who require long-term triple oral
antithrombotic therapy (e.g., patients with ACS managed
with an intracoronary stent and atrial fibrillation requiring
dual antiplatelet therapy and oral anticoagulation) are at
high risk of bleeding, a European Society of Cardiology
Consensus document recommends assessment of hemor-
rhagic risk and tailored therapy to reduce bleeding (78).
These guidelines suggest shortened courses of dual anti-
platelet therapy (6 months for drug-eluting stents) com-
bined with warfarin targeting an international normalized
ratio of 2.0 to 2.5 in patients receiving either drug-eluting or
bare metal stents, provided that the patient is at low to
intermediate risk for hemorrhage. Meanwhile, patients at
high risk for hemorrhage should receive a bare metal stentand only 4 weeks of triple therapy. A new outpatient
bleeding risk index developed for patients undergoing cor-
onary stenting who need long-term oral anticoagulation
seems to be useful for identifying patients at high risk of
bleeding (79).
Such a bleeding risk index might also be useful to identify
patients post-ACS most likely to benefit from novel oral
anticoagulant agents (e.g., factor IIa or Xa inhibitors) who
are receiving dual antiplatelet therapy. This was highlighted
by the premature termination of the APPRAISE-2 trial
(80), which studied the combination of triple therapy
post-ACS and suggests that such therapy may not be safe in
older patients and in other patients at increased risk for
bleeding. The results of the ATLAS-ACS 2 TIMI 51 trial
evaluating the addition of the oral anti-Xa agent rivaroxaban
to antiplatelet therapy in 15,526 patients will be available in
late 2011 (81).
Invasive Management
Key papers in the area of invasive management focused on
the timing of coronary angiography, a comparison of out-
comes between different stents, and 2 large studies in
patients with left main disease who were randomized to PCI
versus CABG.
A meta-analysis of 4 trials with 4,013 patients with
NSTE-ACS compared an early-invasive (time to angiogra-
phy ranging from 1.2 to 14 hours) with a delayed-invasive
(angiography in 21 to 86 h) strategy (82). There were no
differences in death or in MI rates, but the early-invasive
approach was associated with a 41% reduction in the risk of
recurrent ischemia (p  0.02), a 28% reduction in the
duration of hospital stay (p  0.001), trends toward fewer
bleeds (relative risk [RR]: 0.78; p  0.13), and major
adverse cardiovascular events (death, MI, or stroke RR:
0.91; p  0.09).
A propensity-matched analysis of 4,776 pairs of patients
with NSTEMI from the New York State PCI registry
compared outcomes for patients receiving drug-eluting
stents versus bare metal stents over a median follow-up of
3.7 years (83). Mortality differences in favor of drug-eluting
stents were seen beginning at 6 months (2.9% vs. 4.3%; p
0.001) and continuing through 4 years (14.5% vs. 16.6%;
p  0.001). In addition, patients receiving drug-eluting
stents required less frequent need for repeat target vessel
revascularization (11.0% vs. 13.1%; p 0.009). However, in
a randomized trial of 2,314 patients with large (3 mm)
coronary arteries, one third of whom had unstable angina,
there were no statistical differences in death or MI rates
between either sirolimus- or everolimus-eluting stents and
bare-metal stents (84). However, when compared with the
use of bare-metal stents, target vessel revascularization was
reduced by more than one-half with use of either drug-
eluting stent, with no differences between sirolimus and
everolimus. Similarly, 2 randomized trials comparing 2 new
drug-eluting stents (zotarolimus vs. everolimus) in patients,
o
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stent-related or clinical outcomes (85,86).
Since the initial unstable angina guideline published in
1994 (87), left main coronary artery stenosis 50% or higher
was considered to be an indication for CABG. However,
with the introduction of better interventional devices and
improvements in adjunctive therapies during PCI, the
question of whether PCI might be a reasonable alternative
has been raised.
A randomized trial in patients, one-half of whom had
ACS, with unprotected left main coronary artery stenosis,
demonstrated that sirolimus-stenting was noninferior to
CABG with respect to the primary composite of cardiac or
cerebrovascular events at 1 year (88). However, this trial is
difficult to interpret because the event rate was only two-
thirds of that anticipated and the noninferiority bounds
were wide. Furthermore, as was seen in the subanalysis from
the SYNTAX trial (89) and a second small randomized trial
(90), PCI is associated with greater need for subsequent
revascularization than CABG in patients with left main
coronary artery disease, especially among those at highest
risk as defined by a SYNTAX score33 (89). Furthermore,
in these patients, CABG is more effective in relieving
angina (91). The current NSTE-ACS guideline (3) recom-
mends CABG (Class IA) for patients with significant left
main stenosis, and reserves PCI for patients not eligible for
CABG or in whom emergent revascularization is needed
due to hemodynamic instability (Class IIa-B).
Lipid-Lowering Therapies
New data on lipid-lowering therapies in patients with NSTE-
ACS in the past year included research on the current use of
statins and exploration of newer, more potent treatments. Data
from hospitals participating in the CRUSADE and ACTION
registries demonstrated several opportunities for improvement
in lipid management (92). Of patients admitted with ACS
with a low-density lipoprotein level 100 mg/dl, only 37%
had their statin dose uptitrated, as recommended by current
guidelines (3). Furthermore, although 89% were receiving
lipid-lowering therapy at discharge, 70% of patients did not
achieve the more stringent goal of 70 mg/dl for patients
post-ACS. A major barrier seems to be the underutilization
of intensive lipid-lowering regimens that achieve 50%
reduction in low-density lipoprotein (i.e., atorvastatin 40 to
80 mg, rosuvastatin 20 to 40 mg, combinations of ezetimibe
and statin). In the GWTG-CAD registry, only 38% of the
25,036 patients admitted with ACS were receiving an
intensive lipid-lowering regimen at discharge (93).
High-dose statins are limited by hepatic and muscle
toxicity (94) and induce adverse effects on plasma
cholesteryl-ester-transfer protein mass (95). Thus, therapies
that target other lipid particles, such as raising high-density
lipoprotein with a cholesteryl-ester-transfer protein inhibi-
tor (96) or niacin (97), are being studied in Phase III clinical
trials. In patients with ACS, Waksman et al. (98) demon-strated the safety and feasibility of autologous delipidated
high-density lipoprotein plasma infusions. Favorable trends
toward regression in atheromatous plaques were seen, al-
though large-scale clinical trials evaluating the impact on
clinical events are needed before these therapies would be
widely accepted.
Quality
To date, research assessing the quality of care in NSTE-
ACS has focused on acute management, such as early
administration of antithrombotic therapy, beta-blockers,
and coronary angiography in high-risk patients. However,
the late consequences of ACS are frequently underappreci-
ated and hence more attention to post-discharge therapy is
warranted. In an analysis from the GRACE UK-Belgian
Study, 5-year morbidity and mortality rates in patients after
NSTE-ACS were as high as in patients with STEMI (99).
Optimal therapy post–NSTE-ACS was delivered to only
23% of patients in a Canadian registry (100). This low rate
f guideline-recommended therapy was most commonly
ttributed to the treating physician’s belief that the patient
acked high-risk features and/or that there was no evidence
o support the use of the guideline-recommended therapy in
hat clinical situation—reasons that were not supported by
etrospective review of the data. Greater awareness of the
vidence base, guideline recommendations, and coordina-
ion between caregivers (e.g., regarding the administration
f influenza vaccines post-ACS [101]) are required to
urther improve patient care.
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